Fast in vivo imaging of amyloid plaques using μ-MRI Gd-staining combined with ultrasound-induced blood-brain barrier opening

NeuroImage

Volumn 79, Issue , 2013, Pages 288-294

  Santin, Mathieu D ^a,e   Debeir, Thomas ^b   Bridal, S Lori ^c,d   Rooney, Thomas ^b   Dhenain, Marc ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b SANOFI   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d CNRS   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Alzheimer; Amyloid; Blood brain barrier; Microbubbles; MRI; Ultrasound

Indexed keywords

AMYLOID PRECURSOR PROTEIN; GADOTERATE MEGLUMINE; PRESENILIN 1; SONOVUE;

AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG PENETRATION; FEMALE; IMAGE PROCESSING; IN VIVO STUDY; MICROBUBBLE; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOSENSITIVITY; SIGNAL DETECTION; TIME; TRANSGENIC MOUSE; ULTRASOUND TRANSDUCER;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CONTRAST MEDIA; HETEROCYCLIC COMPOUNDS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; ORGANOMETALLIC COMPOUNDS; PLAQUE, AMYLOID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SONICATION; STAINING AND LABELING;

EID: 84878377304     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2013.04.106     Document Type: Article

References (45)

1. Ballantine H.T., Bell E., Manlapaz J. Progress and problems in the neurological applications of focused ultrasound. J. Neurosurg. 1960, 17:858-876.
2. Beccaria K., Canney M., Goldwirt L., Fernandez C., Adam C., Piquet J., Autret G., Clement O., Lafon C., Chapelon J.-Y., Carpentier A. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J. Neurosurg. 2013, (in press).
3. Berghorn K.A., Bonnett J.H., Hoffman G.E. cFos immunoreactivity is enhanced with biotin amplification. J. Histochem. Cytochem. 1994, 42:1635-1642.
4. Blanchard V., Moussaoui S., Czech C., Touchet N., Bonici B., Planche M., Canton T., Jedidi I., Gohin M., Wirths O., Bayer T.A., Langui D., Duyckaerts C., Tremp G., Pradier L. Time sequence of maturation of dystrophic neurites associated with Ab deposits in APP/PS1 transgenic mice. Exp. Neurol. 2003, 184:247-263.
5. Braakman N., Matysik J., van Duinen S.G., Verbeek F., Schliebs R., de Groot H.J., Alia A. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J. Magn. Reson. Imaging 2006, 530-536.
6. Chamberlain R., Reyes D., Curran G.L., Marjanska M., Wengenack T.M., Poduslo J.F., Garwood M., Jack C.R. Comparison of amyloid plaque contrast generated by T2-weighted, T2*-weighted, and susceptibility-weighted imaging methods in transgenic mouse models of Alzheimer's disease. Magn. Reson. Med. 2009, 61:1158-1164.
7. Choi J.J., Pernot M., Small S.A., Konofagou E.E. Noninvasive, transcranial and localized opening of the blood-brain barrier using focused ultrasound in mice. Ultrasound Med. Biol. 2007, 33:95-104.
8. Choi J.J., Selert K., Gao Z., Samiotaki G., Baseri B., Konofagou E.E. Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J. Cereb. Blood Flow Metab. 2011, 31:725-737.
9. Delatour B., Guegan M., Volk A., Dhenain M. In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiol. Aging 2006, 27:835-847.
10. Dhenain M., Privat N., Duyckaerts C., Jacobs R.E. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed. 2002, 15:197-203.
11. Dhenain M., Delatour B., Walczak C., Volk A. Passive staining: a novel ex vivo MRI protocol to detect amyloid deposits in mouse models of Alzheimer's disease. Magn. Reson. Med. 2006, 55:687-693.
12. Dhenain M., El Tannir El Tayara N., Wu T.-D., Guegand M., Volk A., Quintana C., Delatour B. Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiol. Aging 2009, 30:41-53.
13. Doraiswamy P.M., Sperling R.A., Coleman R.E., Johnson K.A., Reiman E.M., Davis M.D., Grundman M., Sabbagh M.N., Sadowsky C.H., Fleisher A.S., Carpenter A., Clark C.M., Joshi A.D., Mintun M.A., Skovronsky D.M., Pontecorvo M.J. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
14. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharmacol. Res. 1999, 16:1564-1569.
15. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
16. Howles G.P., Bing K.F., Qi Y., Rosenzweig S.J., Nightingale K.R., Johnson G.A. Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood-brain barrier with ultrasound. Magn. Reson. Med. 2010, 64:995-1004.
17. Howles G.P., Qi Y., Johnson G.A. Ultrasonic disruption of the blood-brain barrier enables in vivo functional mapping of the mouse barrel field cortex with manganese-enhanced MRI. NeuroImage 2010, 50:1464-1471.
18. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14164-14169.
19. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv. Drug Deliv. Rev. 2008, 60:1209-1217.
20. Hynynen K., McDannold N., Vykhodtseva N., Jolesz F.A. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001, 220:640-646.
21. Jack C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Adriany G., Poduslo J.F. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25:10041-10048.
22. Jordao J.F., Ayala-Grosso C.A., Markham K., Huang Y., Chopra R., McLaurin J., Hynynen K., Aubert I. Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-beta plaque load in the TgCRND8 mouse model of Alzheimer's disease. PLoS One 2011, 5:e10549.
23. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55:306-319.
24. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25:10598-10606.
25. Maeda J., Zhang M.R., Okauchi T., Ji B., Ono M., Hattori S., Kumata K., Iwata N., Saido T.C., Trojanowski J.Q., Lee V.M., Staufenbiel M., Tomiyama T., Mori H., Fukumura T., Suhara T., Higuchi M. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 2011, 31:4720-4730.
26. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9:702-716.
27. Marquet F., Tung Y.S., Teichert T., Ferrera V.P., Konofagou E.E. Noninvasive, transient and selective blood-brain barrier opening in non-human primates in vivo. PLoS One 2011, 6:e22598.
28. McDannold N., Vykhodtseva N., Raymond S., Jolesz F.A., Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 2005, 31:1527-1537.
29. McDannold N., Vykhodtseva N., Hynynen K. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med. Biol. 2008, 34:930-937.
30. McDannold N., Arvanitis C.D., Vykhodtseva N., Livingstone M.S. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res. 2012, 72:3652-3663.
31. Meadowcroft M.D., Connor J.R., Smith M.B., Yang Q.X. MRI and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. J. Magn. Reson. Imaging 2009, 29:997-1007.
32. O'Reilly M.A., Hynynen K. Ultrasound enhanced drug delivery to the brain and central nervous system. Int. J. Hyperthermia 2012, 28:386-396.
33. O'Reilly M.A., Waspe A.C., Ganguly M., Hynynen K. Focused-ultrasound disruption of the blood-brain barrier using closely-timed short pulses: influence of sonication parameters and injection rate. Ultrasound Med. Biol. 2011, 37:587-594.
34. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego. second ed.
35. Petiet A., Santin M., Bertrand A., Wiggins C.J., Petit F., Houitte D., Hantraye P., Benavides J., Debeir T., Rooney T., Dhenain M. Gadolinium-staining reveals amyloid plaques in the brain of Alzheimer's transgenic mice. Neurobiol. Aging 2012, 33:1533-1544.
36. Poduslo J.F., Wengenack T.M., Curran G.L., Wisniewski T., Sigurdsson E.M., Macura S.I., Borowski B.J., Jack C.R. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11:315-329.
37. Poisnel G., Dhilly M., Moustie O., Delamare J., Abbas A., Guilloteau D., Barre L. PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol. Aging 2012, 33:2561-2571.
38. Rasband W.S. ImageJ, U. S. 1997-2012, http://imagej.nih.gov/ij/, National Institutes of Health, Bethesda, Maryland, USA.
39. Sigurdsson E.M., Wadghiri Y.Z., Mosconi L., Blind J.A., Knudsen E., Asuni A., Scholtzova H., Tsui W.H., Li Y., Sadowski M., Turnbull D.H., de Leon M.J., Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 2008, 29:836-847.
40. Sperling R.a, Aisen P.S., Beckett L.a, Bennett D.a, Craft S., Fagan A.M., Iwatsubo T., Jack C.R., Kaye J., Montine T.J., Park D.C., Reiman E.M., Rowe C.C., Siemers E., Stern Y., Yaffe K., Carrillo M.C., Thies B., Morrison-Bogorad M., Wagster M.V., Phelps C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 2011, 7:280-292.
41. Thomas C., Chenu E., Walczak C., Plessis M., Perin F., Volk A. Morphological and carbogen-based functional MRI of a chemically induced liver tumor model in mice. Magn. Reson. Med. 2003, 50:522-530.
42. Treat L.H., McDannold N., Zhang Y., Vykhodtseva N., Hynynen K. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med. Biol. 2012, 38:1716-1725.
43. Vykhodtseva N.I., Hynynen K., Damianou C. Histologic effects of high intensity pulsed ultrasound exposure with subharmonic emission in rabbit brain in vivo. Ultrasound Med. Biol. 1995, 21:969-979.
44. Vykhodtseva N., McDannold N., Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008, 48:279-296.
45. Zaim Wadghiri Y., Sigurdsson E.M., Sadowski M., Elliott J.I., Li Y., Scholtzova H., Tang C.Y., Aguilnaldo G., Pappolla M., Duff K., Wisniewski T.M., Turnbull D.H. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 2003, 50:293-302.